Absci Corporation, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced that it has entered into a research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) using Absci’s AI-powered Integrated Drug Creation™ Platform.